Trial reportJAMA neurology2013
Interleukin 17F level and interferon β response in patients with multiple sclerosis.
Trial report in JAMA neurology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- The Role of Selected Interleukins in the Development and Progression of Multiple Sclerosis-A Systematic Review.International journal of molecular sciences · 2024Pooled it
- Measurement of IL-17AA and IL-17FF as Pharmacodynamic Biomarkers to Demonstrate Target Engagement in the Phase I Study of MCAF5352A.The AAPS journal · 2018Trial
- The toxic components, toxicological mechanism and effective antidote forActa pharmaceutica Sinica. B · 2025Article
- Biomarker panel increases accuracy for identification of an MS relapse beyond sNfL.Multiple sclerosis and related disorders · 2022Article
- Interferon-β Intensifies Interleukin-23-Driven Pathogenicity of T Helper Cells in Neuroinflammatory Disease.Cells · 2021Article
- ADAM12 is a costimulatory molecule that determines Th1 cell fate and mediates tissue inflammation.Cellular & molecular immunology · 2021Article
- Induction or aggravation of other immune-mediated disorders by disease-modifying therapy in treatment of multiple sclerosis.Iranian journal of neurology · 2018Review
- Blood lymphocyte subsets identify optimal responders to IFN-beta in MS.Journal of neurology · 2018Article
- Blood Biomarkers as Outcome Measures in Inflammatory Neurologic Diseases.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2017Review
- Th1 and Th17 Cells and Associated Cytokines Discriminate among Clinically Isolated Syndrome and Multiple Sclerosis Phenotypes.Frontiers in immunology · 2017Article
- Review
- Cytokine profiles show heterogeneity of interferon-β response in multiple sclerosis patients.Neurology(R) neuroimmunology & neuroinflammation · 2016Article
- Body fluid biomarkers for multiple sclerosis--the long road to clinical application.Nature reviews. Neurology · 2015Review
- Body fluid biomarkers in multiple sclerosis: how far we have come and how they could affect the clinic now and in the future.Expert review of clinical immunology · 2015Review
- Cytokines as Biomarkers of Treatment Response to IFN β in Relapsing-Remitting Multiple Sclerosis.Multiple sclerosis international · 2014Article
- Defining and scoring response to IFN-β in multiple sclerosis.Nature reviews. Neurology · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 8 institutions in 5 countries.
Funding
Abstract
importanceHigh serum levels of interleukin 17F (IL-17F) at baseline have been associated with suboptimal response to interferon beta in patients with relapsing-remitting multiple sclerosis.
objectiveTo further investigate the role of IL-17F in predicting treatment response to interferon beta-1b in patients with relapsing-remitting multiple sclerosis using the Singulex Erenna IL-17F immunoassay. DESIGN, SETTING, AND PATIENTS: Serum samples were analyzed from 239 randomly selected patients treated with interferon beta-1b, 250 μg, for at least 2 years in the Betaferon Efficacy Yielding Outcomes of a New Dose Study. EXPOSURE: Treatment with interferon beta-1b, 250 μg, for at least 2 years.
main outcome measuresLevels of IL-17F at baseline and month 6 as well as the difference between the IL-17F levels at month 6 and baseline were compared between the following: (1) patients with less disease activity vs more disease activity; (2) patients with no disease activity vs some disease activity; and (3) responders vs nonresponders.
resultsLevels of IL-17F measured at baseline and month 6 did not correlate with lack of response to treatment after 2 years using clinical and magnetic resonance imaging criteria. Relapses and new lesions on magnetic resonance imaging were not associated with pretreatment serum IL-17F levels. When patients with neutralizing antibodies were excluded, the results did not change. All patients with levels of IL-17F greater than 200 pg/mL were associated with poor response with some clinical or radiological activity. CONCLUSIONS AND RELEVANCE: An increase of IL-17F before and early after treatment with interferon beta-1b was not associated with poor response. These data do not support the value of IL-17F as a treatment response indicator for therapy of patients with multiple sclerosis with interferon beta, although high levels of IL-17F greater than 200 pg/mL may predict nonresponsiveness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.